We are comprised of a dedicated group of scientists focused on developing next-generation therapeutics to treat chronic diseases. We use PASylation® a proprietary and powerful chemistry platform to design novel long-acting peptides with fine-tuned pharmacologic and pharmacokinetic properties to create promising therapeutics for multiple chronic diseases. At Antlia Bioscience, we are driven to make a profound difference in the treatment of cardiovascular and pulmonary diseases. Our work is supported by world-class advisors and collaborators who are all aligned with our vision to bring life-changing therapies to the market.
| Website | http://www.antliabio.com |
| Employees | 5 (3 on RocketReach) |
| Founded | 2021 |
| Phone | +1 619-990-0290 |
| Industry | Biotechnology, Drug Discovery |
| Keywords | Therapeutics, Peptides, Biotechnology, Pharmaceutical, Drug Development, Next Generation Medicine, Protein Therapeutics, Precision Medicine, Novel Therapeutics, Drug Discovery, Biopharma, Pharmaceutical Research, Life Sciences, Clinical Development, Bioconjugation, Therapeutic Peptides, Advanced Therapeutics |
Looking for a particular Antlia Bioscience employee's phone or email?
Marius Sumandea is the Chief Development Officer of Antlia Bioscience.
3 people are employed at Antlia Bioscience.
Antlia Bioscience is based in Encinitas, California.